RESEARCH

Serum and salivary tissue transglutaminase IGA (tTG-IGA) level in celiac patients

Mehran Ajdani1, Nazanin Mortazavi2*, Sima Besharat3, Saeed Mohammadi4, Taghi Amiriani3, Ahmad Sohrabi5, Alireza Norouzi3 and Ghezeljeh Edris3

Abstract

Background: Celiac disease (CD) is a genetically determined autoimmune disease triggered by gluten consumption. Patients with these conditions have intraepithelial lymphocytosis, crypt hyperplasia, and severe intestinal atrophy. Gluten elimination is the only way to reduce this chronic inflammation. The diagnosis of CD is usually made by analyzing anti-tTG, anti-DGP, or EMA serological tests, and it is confirmed by biopsy of the duodenum.

In people with CD, xerostomia or dry mouth is a common complication. This condition causes the salivary glands to malfunction and, in turn, may result in oral plaque and periodontal disease.

By comparing salivary and serum levels of tissue transglutaminase IgA (tTG-IgA), this study aims to suggest a non-invasive method for diagnosis of CD. Furthermore, the present study evaluates the severity of xerostomia symptoms in people with CD.

Methods: In this case–control study, participants were patients referred to the internal ward of Sayyad Shirazi hospital. The control group was selected from healthy people who attended Gorgan Dental College.

In this study, an analysis of serum was performed following consent from patients. This was followed by a salivary test, and the results of both tests were compared.

The Xerostomia Inventory questionnaire was also used to determine the severity of xerostomia. As part of this study, examination of factors such as total protein concentration of saliva, albumin concentration, amylase level, pH, sodium, calcium, potassium, phosphorus, and interleukin (6, 18, and 21) were conducted.

Results: A total of 78 people were studied (aged 15 to 68), 26 were male (33.3%) and 52 were female (66.7%). In comparisons of the serum and saliva of people with and without CD, the level of amylase was higher in the latter group. The average levels of IL-6, IL-18, IL-21, and salivary and serum tTG were higher in people with CD. Additionally, CD patients were more likely to develop xerostomia.

Conclusion: Study findings showed that CD can reduce certain salivary enzymes and elements, as well as increase inflammatory cytokines, salivary, and serum tTG.

The management of dry mouth should also be recommended for celiac disease patients in order to prevent its complications.

Keywords: Celiac disease, Serologic test, Saliva, Xerostomia, Interleukins

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
infiltration of inflammatory cells into the lamina propria, crypt hyperplasia, and villous atrophy, and CD is the leading cause of villous atrophy [2, 3].

It is estimated that the pooled global seroprevalence of CD in 2018 is 1.4%, while the pooled global prevalence of biopsy-confirmed CD is 0.7%, with the highest prevalence being in Europe (0.8%) and Oceania (0.8%), and the lowest in South America (0.4%) [4]. For studies that used serological methods for diagnosis, CD prevalence in Iran was estimated at 3% (95% CI 0.03–0.03) and 2% (95% CI 0.01–2.0%), for those that used biopsy methods [5].

Despite increasing awareness of the disease, the CD is believed to be underdiagnosed [6]. The preferred serologic test for detecting CD is IgA anti-tissue transglutaminase antibody (tTG IgA), which delivers high sensitivity (93%) and specificity (95%) [3]. Another test commonly used is IgA anti-endomysial antibody (EMA) which is the most specific of all assays, along with IgG-based test antibodies like anti-deaminated gliadin peptide or tTG antibodies for IgA deficient individuals [3]. tTG is a calcium-dependent enzyme that catalyzes the formation of ε-(γ-glutamyl) lysine bonds between glutamine and lysine residues in body fluids and tissues. Gliadin is a substrate for tTG, which deaminates the glutamine residues in gliadin, causing gut-derived T cells to recognize gliadin and activate an immune response [7]. The gold standard for the diagnosis of CD is antibody testing followed by a biopsy of the duodenum [8].

In addition to plasma, autoantibodies produced in CD by ingestion of gluten-containing foods also appear in saliva, but in smaller concentrations than in blood [9]. Although the tTG IgA concentration in human saliva is smaller than in blood, it is a noninvasive technique that bypasses the unpleasant process of collecting blood samples. Human recombinant tTG in a fluid-phase radioimmunoassay (RIA) format was most sensitive in detecting tTG-Abs [2]. Saliva versus serum RIA has a specificity of 100%, whereas the sensitivity is 97.4% [10]. An enzyme-linked immunomagnetic electrochemical (ELIME) assay was also developed for measuring serum tTG in saliva [11].

The present study aimed to investigate the correlation between salivary and serum tTG-Ab.

Methods

Study design

The present case–control study was conducted in Gorgan city, northeast of Iran. Subjects were patients that were referred to the internal ward of Sayyad Shirazi hospital. By gender matching, the control group was selected from healthy people referred to Gorgan Dental College. Subjects in the case group were on a gluten-free diet (GFD). The ethics committee of Golestan University of Medical Sciences approved the protocol.

Definition

The European Society of Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) guidelines and AGA Clinical Practice Update on Diagnosis and Monitoring of Celiac Disease suggest diagnostic criteria for CD. The guidelines state it depends upon gluten-dependent CD symptoms (particularly malabsorption), CD-specific antibody levels (high serum TGA IgA levels ≥ 10 × ULN) as criteria for CD diagnosis without a biopsy. Also, in the absence of a biopsy, the CD diagnosis should be confirmed with a positive EMA-IgA test in a second blood sample. Villous atrophy and crypt hyperplasia observed in a biopsy of the duodenum are histopathologic findings associated with HLA-DQ2 and/or HLA-DQ8. This study used ESPGHAN as an inclusion criterion for CD diagnosis in pediatrics, and AGA Clinical Practice Update to diagnose CD in adults [12, 13]. Patients with denture use, xerostomia due to another systemic disease, and selective IgA deficiency were excluded from the study.

The Xerostomia Inventory (XI) questionnaire was also used to evaluate the severity of xerostomia.

Procedure

Informed consent was obtained from subjects before collecting serum and saliva samples. Following receipt of serum samples, the samples were stored at −20 °C until analysis. During the clinical examination, the resting whole saliva was collected by the spit method. During the morning hours of 8 a.m. to 10 a.m., samples of saliva were collected into chilled, graduated glass tubes. Prior to sampling, donors were asked to refrain from eating, smoking, drinking (except water), using a mouth rinse, and brushing their teeth for at least one-hour Participants were instructed to spit into a plastic tube to collect saliva samples. The process took ten minutes to complete. A set of collected samples was placed on ice, and the samples were spun at 40 °C for 10 min at 10,000 rpm within two hours [10].

Subjects were also asked to complete an international validated XI questionnaire designed for quantifying the severity of dry mouth symptoms [14]. The XI contains 11 items on a 5-point Likert scale that describe the severity of mouth dryness on a scale ranging from 11 to 55. There are five options per response item: “Never”, “Hardly ever”, “Occasionally”, “Frequently”, and “Always” [15].
Biochemical measurement
Based on the manufacturer’s protocol, salivary and serum tTG-IgA antibody enzymes and inflammatory cytokines (IL-6, IL-18, and IL-21) were measured by ELISA.

Furthermore, physical and chemical factors such as total protein concentration in saliva, amylase level, albumin concentration, pH, sodium, calcium, potassium, and phosphorus were evaluated.

Statistical analysis
Quantitative data were described using mean and standard deviation and qualitative data were described based on the frequency and relative frequency. The Kolmogorov–Smirnov test was used to determine whether the data were normally distributed. Assuming the data were normal, the homogeneity of variance was determined using Leven’s test. The mean values of the studied variables were compared based on independent t-tests in the homogeneity of variance situation. The Welch t-test is applied if the variances are not homogeneous. A Mann–Whitney U test was used if there were any abnormalities. Comparing the means of quantitative variables if data differences are normal was conducted using the paired t-test and otherwise the Wilcoxon signed-rank test.

Comparisons of qualitative data were conducted using the Chi-square test or Fisher’s exact test.

The XI questionnaire resulted in a Cronbach’s alpha coefficient of 0.87, indicating reliable internal consistency. The questionnaire was evaluated in two groups of case and control participants.

In receiver operating characteristic (ROC) analysis, the area under the curve (AUC) was used to estimate the predictive power of salivary indicators. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and false discovery rate (FDR) were calculated.

All tests were two-sided, and P < 0.05 was regarded as statistically significant. Statistical analyses were conducted using R (v4.1.0).

Results
A total of 78 individuals aged 15 to 68 participated in the study. The mean and SD of age in the case and control groups were 39.18 ± 11.26 and 34.31 ± 7.23, respectively. The overall gender distribution was 26 (33.7%) male (15 cases, 11 controls) and 52 female (24 cases, 28 controls). A total of 14 patients has experienced disease under five years and 25 have been affected for over five years.

Xerostomia assessment showed statistically significant differences between case and control groups. The levels of xerostomia were significantly higher in CD patients (2.44 ± 0.71) than in healthy control subjects (1.91 ± 0.69) (p-value = 0.001). The results of the XI questionnaire are presented in Table 1.

The mean salivary pH, calcium, phosphorus, sodium, potassium, albumin, and total protein difference between the case and control groups were not statistically significant. The mean amylase in the case group was significantly lower than that in the control group. The mean levels of IL-18, IL-6, and IL-21 in the case group were significantly higher than those in the control group as shown in Table 2.

Mean salivary and serum tTG in the case group (1822.37 ± 2232.81 and 152.72 ± 47.57), compared with salivary and serum tTG in the control group (95.04 ± 183.20 and 3.58 ± 2.92), were significantly higher. Boxplot distributions for salivary tTG in case and control groups can be seen in Table 2 and Fig. 1. The plot

| Items                                             | Never number (%) | Hardly ever number (%) | Occasionally number (%) | Frequently number (%) | Always number (%) |
|---------------------------------------------------|-------------------|------------------------|-------------------------|-----------------------|-------------------|
| I sip liquids to aid in swallowing food            | 25 (32.1)         | 19 (24.4)              | 17 (21.8)               | 11 (14.1)             | 6 (7.7)           |
| My mouth feels dry when eating a meal             | 35 (44.9)         | 19 (24.4)              | 19 (24.4)               | 3 (3.8)               | 2 (2.6)           |
| I get up at night to drink                        | 32 (41)           | 10 (12.8)              | 33 (42.3)               | 3 (3.8)               | 0 (0)             |
| My mouth feels dry                                | 25 (32.1)         | 18 (23.1)              | 24 (30.8)               | 7 (9)                 | 4 (5.1)           |
| I have difficulty in eating dry foods             | 20 (25.6)         | 19 (24.4)              | 23 (29.5)               | 12 (15.4)             | 4 (5.1)           |
| I suck sweets or cough lollies to relieve dry mouth | 61 (78.2)      | 8 (10.3)               | 8 (10.3)               | 1 (1.3)               | 0 (0)             |
| I have difficulties swallowing certain foods      | 32 (41)           | 19 (24.4)              | 19 (24.4)               | 6 (7.7)               | 2 (2.6)           |
| The skin of my face feels dry                     | 28 (35.9)         | 10 (12.8)              | 25 (32.1)               | 8 (10.3)              | 7 (9)             |
| My eyes feel dry                                 | 38 (48.7)         | 12 (15.4)              | 20 (25.6)               | 7 (9)                 | 1 (1.3)           |
| My lips feel dry                                 | 22 (28.2)         | 7 (9)                  | 28 (35.9)               | 14 (17.9)             | 7 (9)             |
| The inside of my nose feels dry                   | 33 (42.3)         | 11 (14.1)              | 27 (34.6)               | 5 (6.4)               | 2 (2.6)           |
shows that salivary tTG levels in case groups are significantly higher than in control groups.

ROC curve analysis was used to determine the diagnostic value of salivary tTG-IgA. Considering serum tTG as the gold standard, salivary tTG test showed an AUC, sensitivity, specificity, and diagnostic accuracy of 0.9309 (95% CI = 0.8721–0.9896), 98.15%, 80.00%, and 91.67% respectively with a cutoff of 67.97 (Fig. 2 and Table 3).

Table 2 Evaluation of salivary variables in study groups

|                   | CD patients (Mean ± SD) | Control group (Mean ± SD) | p-value |
|-------------------|-------------------------|---------------------------|---------|
| Ph                | 7.78 ± 0.098            | 7.76 ± 0.095              | 0.478   |
| Amylase           | 198.22 ± 84.69          | 812.20 ± 1260.26          | < 0.001 |
| Calcium           | 2.69 ± 2.12             | 2.16 ± 0.848              | 0.655   |
| Phosphorous       | 17.76 ± 8.15            | 17.50 ± 5.03              | 0.764   |
| Albumin           | 116.52 ± 72.26          | 105.85 ± 60.17            | 0.567   |
| Total protein     | 67.44 ± 29.24           | 55.44 ± 15.24             | 0.07    |
| Sodium            | 7.92 ± 4.068            | 6.40 ± 2.50               | 0.393   |
| Potassium         | 23.72 ± 6.74            | 22.78 ± 3.02              | 0.530   |
| IL-18             | 303.28 ± 202.48         | 166.20 ± 105.64           | < 0.001 |
| IL-6              | 9.38 ± 4.94             | 4.93 ± 2.24               | < 0.001 |
| IL-21             | 438.96 ± 194.68         | 339.59 ± 126.58           | 0.021   |
| Salivary tTG      | 1822.37 ± 2232.81       | 95.04 ± 183.20            | < 0.001 |

Discussion

CD is considered a childhood disease, however, up to 20% of adults diagnosed with CD are over 60 years of age [16]. CD manifests itself in a wide range of typical and atypical ways [17–21]. For more than three decades, the CD has been persistently underdiagnosed, and its clinical presentation has changed, leading to difficulties with CD diagnosis [17]. An undetected CD can cause certain complications, such as poor growth, short stature, anemia, neurological issues, liver abnormalities, joint manifestations, dermatitis herpetiformis, osteoporosis, infertility, recurrent aphthous stomatitis, and enamel hypoplasia [22, 23]. The early diagnosis of CD and the treatment with GFD may prevent most of the advanced extraintestinal manifestations. The prognosis for extraintestinal manifestations for children treated with GFD is also better than for adults [23]. Despite the proven benefits of the
GFD, it can be exceedingly difficult to completely avoid gluten-containing foods, and adherence to a GFD is estimated to be only 45–80% [24]. The level of GFD adherence in CD patients was not assessed in the present study. CD, therefore, requires a new diagnostic tool or screening method. In our study, we propose saliva as an alternative to serum serology for the diagnosis of CD. Saliva sampling does not require trained staff, is easy to obtain, prevents accidental exposure to blood, and is inexpensive [25]. In addition, since this method isn’t invasive, it is suitable for diagnosing CD in children.

A comparison of salivary and serum levels of tissue transglutaminase IgA was carried out in this study, and the severity of dry mouth in patients with CD was examined. Patients with CD had higher xerostomia rates compared to healthy controls, indicating that CD can adversely affect oral and dental health. The correlation between salivary and serum tTG-IGA was statistically significant for all subjects, and salivary tTG sensitivity and specificity were comparable to previous studies [2, 10]. Several attempts at detecting salivary CD-specific antibodies were made in previous studies.

The results of the present study showed that CD patients had lower mean amounts of amylase in their saliva than the control group, and this difference was statistically significant. Lenander-Lumikari et al., comparing the saliva of CD patients with that of healthy individuals, found that amylase levels were lower in CD patients, confirming the results of this study [26].

The present study did not find a significant difference between CD patients and healthy individuals in terms of other chemical and physical factors, including albumin, total protein, pH, sodium, calcium, potassium, and phosphorus. Lenander-Lumikari et al. reported that albumin and total protein levels were significantly higher in the saliva of CD patients, whereas saliva flow had no significant difference. The results of the study stand in contrast to the present study [26].

According to the results of this study, the mean level of all three interleukins IL-6, IL-18, IL-21 in CD patients was significantly higher than the control group. The study by Manavalan et al. found that the level of tTG-IgA titer correlated statistically with the level of interleukin cytokines in CD. The study by Garrote et al. on CD examined the pathogenesis and cytokines. It found that gluten consumption triggers the production of IL-6, IL-18, and IL-21 interleukins, which can provoke inflammation. This study’s findings regarding

![Fig. 2 ROC curve of salivary tTG for diagnosis of CD](image)

| Table 3 | Predictive diagnostic accuracy of salivary tTG |
|---------|-----------------------------------------------|
| Best threshold | AUC | Specificity (%) | Sensitivity (%) | Accuracy (%) | NPV (%) | PPV (%) | Precision (%) | FDR (%) |
| 67.97 | 0.93 | 98.15 | 80.00 | 91.67 | 96.00 | 89.83 | 89.83 | 10.17 |
changes in interleukin levels were in agreement with the present study [27].

Conclusion

tTG levels in the blood and saliva of CD patients on GFD may be higher than in healthy individuals. Additionally, CD patients should be advised to manage dry mouth and prevent complications associated with it.

Acknowledgements

Not applicable

Author contributions

MA assisted in Data collection, Original draft preparation. NM assisted in Conceptualization, Methodology, Supervision, Original draft preparation, Review and editing. SB assisted in Conceptualization, Methodology, Supervision, Original draft preparation, Review and editing. SM assisted in Conceptualization, Methodology, Supervision, Original draft preparation, Review and editing. AS assisted in Conceptualization, Methodology, Supervision, Original draft preparation, Review and editing. EGh assisted in Conceptualization, Methodology, Supervision, Original draft preparation, Review and editing. AN assisted in Conceptualization, Methodology, Supervision, Original draft preparation, Review and editing. SB assisted in Conceptualization, Methodology, Supervision, Original draft preparation, Review and editing. MA assisted in Data collection, Original draft preparation. NM assisted in Conceptualization, Methodology, Supervision, Original draft preparation, Review and editing. SM assisted in Conceptualization, Methodology, Supervision, Original draft preparation, Review and editing. AS assisted in Conceptualization, Methodology, Supervision, Original draft preparation, Review and editing. EGh assisted in Data collection, Original draft preparation. All authors have read and approved the final manuscript.

Funding

This study is supported by Golestan University of Medical Sciences (Grant No. 110980). The funding source did not participate in the design of the study, the collection, analysis, and interpretation of data, or in writing the manuscript.

Availability of data and materials

The datasets generated and/or analyzed during the current study are not publicly available due to confidentiality of information but are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

This research was approved by the Ethical Committee of Golestan University of Medical Sciences, Iran (IR.GOUMS.REC.1398.238), which was performed in accordance with the current and seventh edition of the Declaration of Helsinki. Written consent was obtained from all participants after they were informed about the study. Parents or legally authorized representatives provided informed consent for individuals under the age of 18.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

1 Dental Research Center, Golestan University of Medical Sciences, Gorgan, Iran. 2 Department of Oral and Maxillofacial Medicine, School of Dentistry, Golestan University of Medical Sciences, Gorgan, Iran. P.O. Box 4916953363. 3 Golestan Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran. 4 Stem Cell Research Center, Golestan University of Medical Sciences, Gorgan, Iran. 5 Cancer Control Research Center, Cancer Control Foundation, Iran University of Medical Sciences, Tehran, Iran.

Received: 4 May 2022 Accepted: 30 July 2022 Published online: 06 August 2022

References

1. Garrote JA, Gómez-González E, Bernardo D, Arranz E, Chirio F. Celiac disease pathogenesis: the proinflammatory cytokine network. J Pediatr Gastroenterol Nutr. 2008;47:527–32.
2. Bonamico M, Nenna R, Montuori M, Luparia RPL, Turchetti A, Mennini M, Lucantoni F, Masotti D, Magliocca FM, Culasso F. First salivary screening of celiac disease by detection of anti-transglutaminase autoantibodies and radioimmunoassay in 5000 Italian primary schoolchildren. J Pediatr Gastroenterol Nutr. 2011;52(1):17–20.
3. Kowalski K, Mulak A, Jasinska M, Paradowski L. Diagnostic challenges in celiac disease. Adv Clin Exp Med Off Organ Wroclaw Med Univ. 2017;26(4):729–37.
4. Singh R, Arora A, Strand TA, Leffler DA, Catassi C, Green PH, Kelly CP, Ahuja V, Makhara GK. Global prevalence of celiac disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2018;16(6):823–836.e822.
5. Mohammadibakhsh R, Sohrabi R, Salemi M, Mirghafar M, Behzadifar M. Celiac disease in Iran: a systematic review and meta-analysis. Electron J Gastroenterol Hepatol. 2017;9:1–12.
6. Dahlbom I, Nyberg B-L, Berntsson L, Hansson M. Simultaneous detection of IgA and IgG antibodies against tissue transglutaminase: the preferred pre-biopsy test in childhood celiac disease. Scand J Clin Lab Invest. 2016;76(3):208–16.
7. Dahele AVM, Altmus MC, Humphreys K, Ghosh S. Serum IgA tissue transglutaminase antibodies in coeliac disease and other gastrointestinal diseases. QJM Int J Med. 2001;94(1):195–205.
8. Tataguchik H, Asahi S, Aris N, Shabahzadeh B, Al-Dulaimi D, Rostami Nejad M, Rezazi-Tavirani M, Razaghi MR, Zali MR. An updated overview of spectrum of gluten-related disorders: clinical and diagnostic aspects. BMC Gastroenterol. 2020;20(1):1–12.
9. Pasinszki T, Krebsz M. Advances in celiac disease testing. Adv Clin Chem. 2019;91:1–29.
10. Bonamico M, Ferri M, Nenna R, Verrienti A, Di Mario U, Tiberti C. Tissue transglutaminase autoantibody detection in human saliva: a powerful method for celiac disease screening. J Pediatr. 2004;144(5):632–6.
11. Adometto G, Fabiani L, Volpe G, De Stefano A, Martini S, Nenna R, Lucantoni F, Bonamico M, Tiberti C, Moscone D. An electrochemical immunoassay for the screening of celiac disease in saliva samples. Anal Bioanal Chem. 2015;407(23):1789–96.
12. Husby S, Koletsko S, Konnyves AL, Persechino F, Galli G, Persechino S, Valitutti F, Cavalli F, Cervenka J, Grams J, Brand HS. Self-reported oral health and xerostomia in adult patients with celiac disease versus a comparison group. Oral Surg Oral Med Oral Pathol Oral Radiol. 2017;124(2):152–6.
13. Thomson WM, Clambers JM, Spencer AJ, Williams SM. The Xerostomia Inventory: a multi-item approach to measuring dry mouth. Community Dent Health. 1999;16(1):1–7.
14. Salazar LF, de la Torre FN, Jimenez BV, Colon MN, Hernandez JG, Adrados JG. Diagnostic problems in adult celiac disease. Rev Esp Enferm Dig. 2008;100(1):24.
15. Corleto VD, Parisi P, Ziparo C, Evangelisti M, Quatrale G, Di Nardo G. Skin manifestations and coeliac disease in paediatric population. Nutrients. 2021;13(10):3611. https://doi.org/10.3390/nu13103611.
21. Ribaldone DG, Saracco GM, Pellicano R. Pediatric epilepsy and psychiatric comorbidity: could celiac disease diagnosis improve the outcome? Minerva Pediatr. 2018;70(6):634–5.
22. Amato M, Zingone F, Caggiano M, Iovino P, Bucci C, Ciacci C. Tooth wear is frequent in adult patients with celiac disease. Nutrients. 2017;9(12):1321. https://doi.org/10.3390/nu9121321.
23. Laurikka P, Nurminen S, Kvela L, Kurppa K. Extraintestinal manifestations of celiac disease: early detection for better long-term outcomes. Nutrients. 2018;10(8):1015.
24. Leffler DA, Edwards-George J, Dennis M, Schuppan D, Cook F, Franko DL, Blom-Hoffman J, Kelly CP. Factors that influence adherence to a gluten-free diet in adults with celiac disease. Dig Dis Sci. 2008;53(6):1573–81.
25. Li X, Pomares C, Peyron F, Press CJ, Ramirez R, Geraldine G, Cannavo I, Chapey E, Levigne P, Wallon M. Plasmonic gold chips for the diagnosis of Toxoplasma gondii, CMV, and rubella infections using saliva with serum detection precision. Eur J Clin Microbiol Infect Dis. 2019;38(5):883–90.
26. Lenander-Lumikari M, Ihalin R, Lähteenoja H. Changes in whole saliva in patients with coeliac disease. Arch Oral Biol. 2000;45(5):347–54.
27. Manavalan JS, Hernandez L, Shah JG, Konikka J, Nayer AJ, Lee AR, Ciaccio E, Minaya MT, Green PH, Bhagat G. Serum cytokine elevations in celiac disease: association with disease presentation. Hum Immunol. 2010;71(1):50–7.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.